Clene Inc. Advances ALS Treatment Toward Potential FDA Accelerated Approval
TL;DR
Clene announced progress on CNM-Au8 program for ALS and MS, positioning for potential NDA submission, showcasing survival benefits, enhancing competitiveness.
CNM-Au8 therapy targets mitochondrial function, NAD pathway, and reduces oxidative stress, leading to improved neuronal function and survival in ALS and MS patients.
Clene's CNM-Au8 program offers hope for ALS and MS patients by enhancing survival, remyelination, and neuronal repair, aiming to improve quality of life.
Exciting data from Clene's Phase 2 extension shows promising results in improving survival and neuronal repair, offering new possibilities for ALS and MS treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Clene Inc. (NASDAQ: CLNN) has made significant progress in its CNM-Au8 program for amyotrophic lateral sclerosis (ALS), revealing promising clinical results that could pave the way for accelerated regulatory approval. The company is preparing to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2025, supported by compelling survival data and upcoming biomarker analysis.
The most recent data demonstrated that CNM-Au8 significantly improved survival rates in patients with more advanced stages of ALS, a critical finding for a disease with limited treatment options. In addition to ALS research, the company presented Phase 2 extension results for multiple sclerosis (MS), showing potential for remyelination and neuronal repair.
Financially, Clene reported a net loss of $0.8 million for the first quarter, with $9.8 million in cash reserves sufficient to fund operations through the third quarter of 2025. The company's investigational therapy targets mitochondrial function and the NAD pathway while reducing oxidative stress, representing a novel approach to neurological disease treatment.
These developments could represent a significant advancement in neurodegenerative disease management, potentially offering hope for patients with ALS and MS by addressing underlying cellular mechanisms that contribute to disease progression.
Curated from InvestorBrandNetwork (IBN)
